Search Results - "Ifthikharuddin, Jainulabdeen"

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma by Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar

“…Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy…”
Get full text

False‐positive heparin‐PF4 latex immunoturbidimetric assay due to lupus anti‐coagulant interference: a case report by McRae, Hannah L., Moore, Jozal W., Ifthikharuddin, Jainulabdeen J., Refaai, Majed A.

Get full text

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin by Zand, Martin S., Vo, Thuong, Pellegrin, Tina, Felgar, Raymond, Liesveld, Jane L., Ifthikharuddin, Jainulabdeen J., Abboud, Camille N., Sanz, Ignacio, Huggins, Jennifer

“…Current monoclonal antibody therapies for multiple myeloma have had limited success, perhaps due to narrow target specificity. We have previously described the…”
Get full text

Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy by Dib, Elie G., Ifthikharuddin, Jainulabdeen J., Scott, Glynis A., Partilo, Steven R.

Get full text

Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: Case report and literature review by Komrokji, Rami, Ifthikharuddin, Jainulabdeen J., Felgar, Raymond E., Abboud, Camille N., Wedow, Lucy A., Connaughton, Anna, Bennett, John M.

“…Allogeneic hematopoietic stem cell transplantation (SCT) is a potentially curative treatment for patients with myelodysplastic syndrome (MDS). Relapses after…”
Get full text

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001 by Facon, Thierry, Lonial, Sagar, Weiss, Brendan M, Suvannasankha, Attaya, Fay, Joseph, Arnulf, Bertrand, Ifthikharuddin, Jainulabdeen J, de Boer, Carla, Wang, Jianping, Wu, Kaida, Chari, Ajai, Lentzsch, Suzanne, Schecter, Jordan, Krishnan, Amrita

“…Introduction: Daratumumab (DARA) is an anti-CD38 human monoclonal antibody that is approved as a monotherapy and in combination with lenalidomide and…”
Get full text

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma by Chari, Ajai, Lonial, Sagar, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Ifthikharuddin, Jainulabdeen J., Qin, Xiang, Masterson, Tara, Nottage, Kerri, Schecter, Jordan M, Ahmadi, Tahamtan, Weiss, Brendan, Krishnan, Amrita, Lentzsch, Suzanne

“…Introduction: Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody with remarkable safety and activity as monotherapy in heavily treated relapsed…”
Get full text

Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA by Hashmi, Shahrukh, Mooney, Chris, Phillips, Gordon L. II, Liesveld, Jane L., Ifthikharuddin, Jainulabdeen J

“…Abstract 2557 Stem cell transplantation, better supportive care, and the introduction of “novel agents”, particularly proteosome inhibitors and IMIDS, have…”
Get full text

Salvage Autologous Hematpoeitic Stem Cell Transplants (AHSCT2) for Myeloma: Single Center Experience by Faltas, Bishoy, Liesveld, Jane L., Becker, Michael, Ifthikharuddin, Jainulabdeen J., Phillips, Gordon L.

“…Abstract 4591 Although the role of AHSCT1 is well established in multiple myeloma therapy, the role of the salvage (not “tandem”) AHSCT2 is less clear…”
Get full text

A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT by Bensinger, W I, Becker, P S, Gooley, T A, Chauncey, T R, Maloney, D G, Gopal, A K, Green, D J, Press, O W, Lill, M, Ifthikharuddin, J J, Vescio, R, Holmberg, L A, Phillips, G L

“…We aimed to examine whether doses of melphalan higher than 200 mg/m 2 improve response rates when used as conditioning before autologous transplant (ASCT) in…”
Get full text

Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation by Bensinger, William I., Becker, Pamela S, Gooley, Ted A., Chauncey, Thomas, Maloney, David G., Vescio, Robert, Gopal, Ajay K., Green, Damian J., Press, Oliver W., Lill, Michael, Holmberg, Leona, Ifthikharuddin, Jainulabdeen J, Phillips, Gordon L.

“…Abstract 2009 Melphalan 200 mg/m2 has remained the standard of care as a preparative regimen for patients with multiple myeloma (MM) undergoing autologous stem…”
Get full text

Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy by Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph, Arnulf, Bertrand, Kaufman, Jonathan L, Ifthikharuddin, Jainulabdeen, Weiss, Brendan M, Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Ray, Wang, Jim, Masterson, Tara, Nottage, Kerri, Schecter, Jordan, Chiu, Christopher, Khokhar, Nushmia, Ahmadi, Tahamtan, Lonial, Sagar

Get full text

High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices by McMahon, Brandon J., Ifthikharuddin, Jainulabdeen J., Dib, Elie, Chen, Leway, Francis, Charles W., Massey, Todd H.

“…Patients with ventricular assist devices (VAD) are at high risk for thromboembolic complications (TEC) probably due to platelet activation and excessive…”
Get full text

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML by Walker, Alison R, Komrokji, Rami S, Ifthikharuddin, Jainulabdeen, Messina, Patti, Mulford, Deborah, Becker, Michael, Friedberg, Jonathan, Oliva, Jamie, Phillips, Gordon, Liesveld, Jane L, Abboud, Camille

“…Abstract Receptor activated tyrosine kinases such as c-kit, c-fms and PDGFR are known targets of inhibition by imatinib mesylate (Gleevec) and are expressed on…”
Get full text

Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib by Rothberg, Paul G., Vargas, Roberto L., Liesveld, Jane L., Ifthikharuddin, Jainulabdeen J., Frazier, Sharon D., Polochock, Susan L.

“…Chronic myelogenous leukemia (CML) is caused by a balanced translocation between chromosomes 9 and 22 that creates the BCR-ABL fusion gene (FG) and activates…”
Get full text

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) by Phillips, Gordon L., Abboud, Camille N., Bernstein, Steven H., Friedberg, Jonathan W., Becker, Michael W., Ifthikharuddin, Jainulabdeen J., Young, Faith, Liesveld, Jane L.

“…Background: AHSCT is standard therapy for recurrent or progressive, yet chemosensitive lymphoma, both non-Hodgkin's (NHL) and Hodgkin's (HL). However, relapse…”
Get full text

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML by Abboud, Camille N., Walker, Alison, Komrokji, Rami S., Ifthikharuddin, Jainulabdeen J., Sparks, Connie, Likly, Kelly, Messina, Patti, Mulford, Deborah, Friedberg, Jonathan, Becker, Michael W., Young, Faith, Bernstein, Steven H., Salvado, August J., Phillips, Gordon L., Liesveld, Jane L.

“…Background: Receptor activated tyrosine kinases like c-kit, c-fms and PDGFR are known targets of inhibition by imatinib mesylate (Gleevec) and are expressed on…”
Get full text

Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center by Liesveld, Jane L., Abboud, Camille N., Bernstein, Stephen H., Friedberg, Jonathan, Ifthikharuddin, Jainulabdeen J., Constine, Louis S., Kaplan, Karen L., Wedow N.P., Lucy A., Nichols, Diane D., Oliva, Jamie, Etter, Maryanne, Phillips, Gordon L.

“…Conditioning regimens utilized in reduced intensity transplants are designed to optimize immune suppression to allow a graft vs. tumor effect. One reduced…”
Get full text

False-positive heparin-PF4 latex immunoturbidimetric assay due to lupus anti-coagulant interference: a case report by McRae, Hannah L, Moore, Jozal W, Ifthikharuddin, Jainulabdeen J, Refaai, Majed A

Get full text

Isolated splenic blastic transformation of idiopathic myelofibrosis and response to splenectomy by Ifthikharuddin, Jainulabdeen J., Janas, JoAnn, Phatak, Pradyumna D.

Get full text